

# Monty Silverdale Frcp

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3973630/publications.pdf>

Version: 2024-02-01

64  
papers

1,982  
citations

257450

24  
h-index

265206

42  
g-index

64  
all docs

64  
docs citations

64  
times ranked

2312  
citing authors

#	ARTICLE	IF	CITATIONS
1	Altered Pain Processing Associated with Administration of Dopamine Agonist and Antagonist in Healthy Volunteers. <i>Brain Sciences</i> , 2022, 12, 351.	2.3	1
2	Gender gap in deep brain stimulation for Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, 47.	5.3	22
3	<scp>Neuromelaninâ€MRI</scp> to Quantify and Track Nigral Depigmentation in Parkinson's Disease: A Multicenter Longitudinal Study Using Templateâ€Based Standardized Analysis. <i>Movement Disorders</i> , 2022, 37, 1028-1039.	3.9	12
4	Subthalamic Stimulation Improves Quality of Sleep in Parkinson Disease: A 36-Month Controlled Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 323-335.	2.8	21
5	Orofacial pain in 1916 patients with early or moderate Parkinson disease. <i>Pain Reports</i> , 2021, 6, e923.	2.7	9
6	Author response to comment on "The association between pain and impulse control behaviours in Parkinson's disease". <i>Parkinsonism and Related Disorders</i> , 2021, 83, 128-129.	2.2	0
7	Metabolomics of sebum reveals lipid dysregulation in Parkinson's disease. <i>Nature Communications</i> , 2021, 12, 1592.	12.8	91
8	Corneal Confocal Microscopy Identifies Parkinson's Disease with More Rapid Motor Progression. <i>Movement Disorders</i> , 2021, 36, 1927-1934.	3.9	16
9	Tau associated peripheral and central neurodegeneration: Identification of an early imaging marker for tauopathy. <i>Neurobiology of Disease</i> , 2021, 151, 105273.	4.4	14
10	Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The "Exenatide-PD3" study. <i>BMJ Open</i> , 2021, 11, e047993.	1.9	32
11	Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 48.	5.3	23
12	Corneal Confocal Microscopy to Image Small Nerve Fiber Degeneration: Ophthalmology Meets Neurology. <i>Frontiers in Pain Research</i> , 2021, 2, 725363.	2.0	14
13	Evaluation of the effect of bilateral subthalamic nucleus deep brain stimulation on fatigue in Parkinson's Disease as measured by the non-motor symptoms scale. <i>British Journal of Neurosurgery</i> , 2021, , 1-4.	0.8	7
14	Parkinson's Kinetigraph in the Selection of Levodopa-Carbidopa Intestinal Gel for Motor Fluctuations Refractory to Deep Brain Stimulation. <i>Journal of Movement Disorders</i> , 2021, 14, 239-241.	1.3	2
15	Validating Differential Volatilome Profiles in Parkinson's Disease. <i>ACS Central Science</i> , 2021, 7, 300-306.	11.3	20
16	A neurophysiological investigation of anticipation to pain in Parkinson's disease. <i>European Journal of Neuroscience</i> , 2020, 51, 611-627.	2.6	8
17	Objective Analysis of Neck Muscle Boundaries for Cervical Dystonia Using Ultrasound Imaging and Deep Learning. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2020, 24, 1016-1027.	6.3	15
18	Real world use of a neurophysiology service for the differential diagnosis of hyperkinetic movement disorders. <i>Parkinsonism and Related Disorders</i> , 2020, 71, 11-14.	2.2	1

#	ARTICLE	IF	CITATIONS
19	Beneficial nonmotor effects of subthalamic and pallidal neurostimulation in Parkinson's disease. <i>Brain Stimulation</i> , 2020, 13, 1697-1705.	1.6	36
20	The association between pain and impulse control behaviours in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 53-55.	2.2	3
21	Corneal confocal microscopy detects small fibre neurodegeneration in Parkinson's disease using automated analysis. <i>Scientific Reports</i> , 2020, 10, 20147.	3.3	16
22	A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: results at the 36-month follow-up. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 687-694.	1.9	36
23	Pedunculopontine Nucleus Microstructure Predicts Postural and Gait Symptoms in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1199-1207.	3.9	29
24	Beneficial effect of 24-month bilateral subthalamic stimulation on quality of sleep in Parkinson's disease. <i>Journal of Neurology</i> , 2020, 267, 1830-1841.	3.6	17
25	Genome-Wide Association Study of Pain in Parkinson's Disease Implicates <i>TRPM8</i> as a Risk Factor. <i>Movement Disorders</i> , 2020, 35, 705-707.	3.9	7
26	Small Fibre Neuropathy in Parkinson's Disease: Comparison of Skin Biopsies from the More Affected and Less Affected Sides. <i>Journal of Parkinson's Disease</i> , 2019, 9, 761-765.	2.8	14
27	Parkinson's-adapted cognitive stimulation therapy: a pilot randomized controlled clinical trial. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641985221.	3.5	18
28	Globus pallidus deep brain stimulation for Tourette syndrome: Effects on cognitive function. <i>Parkinsonism and Related Disorders</i> , 2019, 69, 14-18.	2.2	5
29	Outcomes from deep brain stimulation targeting subthalamic nucleus and caudal zona incerta for Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2019, 5, 17.	5.3	28
30	Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. <i>Brain</i> , 2019, 142, 3592-3604.	7.6	90
31	EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 353-365.	3.9	126
32	Parkinson's-adapted cognitive stimulation therapy: feasibility and acceptability in Lewy body spectrum disorders. <i>Journal of Neurology</i> , 2019, 266, 1756-1770.	3.6	16
33	Discovery of Volatile Biomarkers of Parkinson's Disease from Sebum. <i>ACS Central Science</i> , 2019, 5, 599-606.	11.3	100
34	Increased Intraepidermal Nerve Fiber Degeneration and Impaired Regeneration Relate to Symptoms and Deficits in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 111.	2.4	9
35	Atypical late presentation of BPAN in a male: A case report. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 184-185.	2.2	1
36	Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 421-430.	3.9	69

#	ARTICLE	IF	CITATIONS
37	Short-term quality of life after subthalamic stimulation depends on non-motor symptoms in Parkinson's disease. <i>Brain Stimulation</i> , 2018, 11, 867-874.	1.6	36
38	Subthalamic Stimulation Improves Quality of Life of Patients Aged 61 Years or Older With Short Duration of Parkinson's Disease. <i>Neuromodulation</i> , 2018, 21, 532-540.	0.8	26
39	Non-motor outcomes of subthalamic stimulation in Parkinson's disease depend on location of active contacts. <i>Brain Stimulation</i> , 2018, 11, 904-912.	1.6	53
40	Quality of life outcome after subthalamic stimulation in Parkinson's disease depends on age. <i>Movement Disorders</i> , 2018, 33, 99-107.	3.9	39
41	Changes in Parkinson's disease sleep symptoms and daytime somnolence after bilateral subthalamic deep brain stimulation in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2018, 4, 16.	5.3	14
42	A detailed clinical study of pain in 1957 participants with early/moderate Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 27-32.	2.2	77
43	5-HT modulation of pain perception in humans. <i>Psychopharmacology</i> , 2017, 234, 2929-2939.	3.1	40
44	Psychosocial therapy for Parkinson's-related dementia: study protocol for the INVEST randomised controlled trial. <i>BMJ Open</i> , 2017, 7, e016801.	1.9	15
45	The perception of affective touch in Parkinson's disease and its relation to small fibre neuropathy. <i>European Journal of Neuroscience</i> , 2017, 45, 232-237.	2.6	25
46	Deep Brain Stimulation for Movement Disorders Other than Parkinson's Disease. , 2017, , 75-105.		1
47	Other movement disorders. <i>Medicine</i> , 2016, 44, 547-551.	0.4	0
48	Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease. <i>Brain Stimulation</i> , 2016, 9, 78-85.	1.6	86
49	Pain in multiple system atrophy and progressive supranuclear palsy compared to Parkinson's disease. <i>Brain and Behavior</i> , 2015, 5, e00320.	2.2	32
50	Small fiber neuropathy in Parkinson's disease: A clinical, pathological and corneal confocal microscopy study. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1454-1460.	2.2	117
51	Bilateral globus pallidus stimulation for severe Tourette's syndrome: a double-blind, randomised crossover trial. <i>Lancet Neurology</i> , The, 2015, 14, 595-605.	10.2	155
52	Dystonia Associated with Idiopathic Slow Orthostatic Tremor. <i>Tremor and Other Hyperkinetic Movements</i> , 2015, 5, 351.	2.0	3
53	Non-Motor Symptoms Profile and Burden in Drug Naïve Versus Long-Term Parkinson's Disease Patients. <i>Journal of Parkinson's Disease</i> , 2014, 4, 541-547.	2.8	41
54	Genomewide association study in cervical dystonia demonstrates possible association with sodium leak channel. <i>Movement Disorders</i> , 2014, 29, 245-251.	3.9	43

#	ARTICLE	IF	CITATIONS
55	Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 452-455.	2.2	38
56	Cerebellar axial postural tremor complicating radiotherapy for prostate cancer. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 680-681.	2.2	1
57	Reversible pseudoathetosis induced by cervical myelopathy. <i>Movement Disorders</i> , 2012, 27, 1370-1371.	3.9	8
58	Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. <i>Synapse</i> , 2010, 64, 177-180.	1.2	65
59	Pramipexole and gender identity disorder: Expanding the phenotype of hypersexuality in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2434-2435.	3.9	8
60	HIV-associated parkinsonism with levodopa-induced dyskinesia and response to highly active antiretroviral therapy. <i>Movement Disorders</i> , 2009, 24, 2441-2442.	3.9	12
61	The spectrum of orolingual tremor—A proposed classification system. <i>Movement Disorders</i> , 2008, 23, 159-167.	3.9	46
62	Topiramate-responsive cerebellar axial postural tremor. <i>Movement Disorders</i> , 2008, 23, 1189-1191.	3.9	7
63	Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 403-409.	3.9	56
64	Potential nondopaminergic drugs for Parkinson's disease. <i>Advances in Neurology</i> , 2003, 91, 273-91.	0.8	10